Format

Send to

Choose Destination
Gynecol Oncol. 2018 Jul;150(1):73-78. doi: 10.1016/j.ygyno.2018.04.563. Epub 2018 Apr 27.

Underutilization of brachytherapy and disparities in survival for patients with cervical cancer in California.

Author information

1
UC San Diego, San Diego, CA, United States. Electronic address: jmayadev@ucsd.edu.
2
California Cancer Registry, Sacramento, CA, United States.
3
UC San Diego, San Diego, CA, United States.
4
UCSF Medical Center, San Francisco, CA, United States.
5
Cedars-Sinai Medical Center, Los Angeles, CA, United States.
6
UC Davis Medical Center, Sacramento, CA, United States.

Abstract

PURPOSE:

The treatment for locally advanced cervical cancer is external beam radiation (EBRT), concurrent chemotherapy, and brachytherapy (BT). We investigated demographic and socioeconomic factors that influence trends in BT utilization and disparities in survival.

METHODS:

Using the California Cancer Registry, cervical cancer patients FIGO IB2-IVA from 2004 to 2014 were identified. We collected tumor, demographic and socioeconomic (SES) factors. We used multivariable logistic regression analysis to determine predictors of use of BT. Using Cox proportional hazards, we examined the impact of BT vs EBRT boost on cause specific (CSS) and overall survival (OS).

RESULTS:

We identified 4783 patients with FIGO stage 11% IB2; 32% II, 54% III, 3% IVA. Nearly half (45%) of patients were treated with BT, 18% were treated with a EBRT boost, and 37% had no boost. Stage II and III were more likely to be treated with BT (p = 0.002 and p = 0.0168) vs Stage IB2. As patients aged, the use of BT decreased. Using multivariate analysis, BT impacted CCS (HR 1.16, p = 0.0330) and OS (HR 1.14, p = 0.0333). Worse CSS was observed for black patients (p = 0.0002), low SES (p = 0.0263), stage III and IVA (p < 0.0001. Black patients, low and middle SES had worse OS, (p = 0.0003).

CONCLUSIONS:

The utilization of BT in locally advanced cervical cancer was low at 45%, with a decrease in CSS and OS. Black patients and those in low SES had worse CSS. As we strive for outcome improvement in cervical cancer, we need to target increasing access and disparities for quality and value.

PMID:
29709291
DOI:
10.1016/j.ygyno.2018.04.563
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for eScholarship, California Digital Library, University of California
Loading ...
Support Center